...
首页> 外文期刊>Cytometry, Part B. Clinical cytometry: the journal of the International Society for Analytical Cytology >Immunophenotypic Heterogeneity of Polytypic Plasma Cells and the Impact on Myeloma Minimal Residual Disease Detection by Multiparameter Flow Cytometry
【24h】

Immunophenotypic Heterogeneity of Polytypic Plasma Cells and the Impact on Myeloma Minimal Residual Disease Detection by Multiparameter Flow Cytometry

机译:聚丙浆细胞免疫蛋白型异质性及对多次流量细胞术的影响最小残余疾病检测

获取原文
获取原文并翻译 | 示例
           

摘要

Background Flow cytometry is widely used for minimal residual disease (MRD) detection in plasma cell myeloma (PCM). Recently, an increasing number of studies have demonstrated that polytypic plasma cells (PPCs) display greater immunophenotypic variation than previously appreciated. Our aim was to further characterize the immunophenotype of PPC in this setting. Methods PPC in 102 bone marrow specimens (93 MRD-negative post-treatment PCM and 9 negative initial evaluations for plasma cell neoplasm) were evaluated by 10-color flow cytometry. Frequency of CD19, CD27, CD28, CD56, CD117, and CD138 expression was assessed. Results All cases showed CD27 and CD19 positivity. CD117 was uniformly negative. Percentage of CD138 expression was variable with one negative case (<20% expression). Percentage of CD28 and CD56 expression was variable and included 11 CD28+ cases as well as 38 CD56+ cases. Forty-two percent (43 of 102) cases showed atypical expression of at least one marker with 36 cases (35%) showing atypical expression of a single marker and 7 cases (7%) showing dual atypical marker expression (CD56+/CD28+). Conclusions Considerable immunophenotypic variation exists in PPC. The assessment of cytoplasmic light chain distribution, in conjunction with surface marker expression, is recommended to avoid diagnostic inaccuracy in MRD evaluation. (c) 2019 International Clinical Cytometry Society
机译:背景技术流式细胞术广泛用于血浆细胞骨髓瘤(PCM)中的最小残余疾病(MRD)检测。最近,越来越多的研究已经证明了多液相色谱(PPC)显示器比先前欣赏更大的免疫表型变化。我们的目的是进一步表征PPC在该环境中的免疫蛋白酶。方法通过1​​0色流式细胞术评价PPC在102骨髓标本(93mRD阴性后治疗PCM和9对血浆细胞肿瘤的9个负初始评价)。评估CD19,CD27,CD28,CD56,CD117和CD138表达的频率。结果所有病例显示CD27和CD19阳性。 CD117均匀负面。 CD138表达的百分比与一个负案例(<20%表达)变化。 CD28和CD56表达的百分比是可变的,包括11个CD28 +病例以及38个CD56 +病例。 42%(43个中的43个)病例显示了至少一种标记的非典型表达,具有36例(35%),显示单个标记的非典型表达,7例(7%)显示双非型标记表达(CD56 + / CD28 +)。结论PPC中存在相当大的免疫蛋白型变异。建议使用表面标志物表达的细胞质轻链分布评估以避免MRD评估中的诊断不准确。 (c)2019年国际临床细胞计量

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号